Please login to the form below

biologics

This page shows the latest biologics news and features for those working in and with pharma, biotech and healthcare.

China’s Innovent to start US trials of anti-CD47 cancer drug

Sintilimab will be initially positioned for the Chinese market. Chinese biotech Innovent Biologics has been given approval by the FDA to start trials of an antibody that targets CD47, an emerging

Latest news

Novartis cuts manufacturing jobs in Switzerland and UK

This reflects the move away from simpler small molecule-based pills towards a greater reliance on biologics and the new and highly complex manufacturing required for cell therapies, such as
London cancer hub launched by Cancer Research UK

The first research programme is aimed at discovering and developing new biologic cancer drugs, with an emphasis on the tumour microenvironment (TME) – i.e. ... Programme two will use imaging techniques to see how biologic treatments, such as cell
Gilead and Galapagos JAK contender scores in RA trial

drugs to help patients with active RA who don’t respond adequately to current biologics.
New data keeps AbbVie’s star pipeline therapies on track

For risankizumab, the new data could be important to help AbbVie differentiate its IL-23 inhibitor from a clutch of new biologic therapies for psoriasis from Novartis, Eli Lilly and Johnson
BMS psoriasis drug hits the mark in phase II

competitive with many biologic therapies approved in the setting, ”according to analyst Matt Phipps of William Blair. ... greater improvement (PASI 75) at week 12 in 75% of patients overall, and 81% of those previously treated with a biologic drug.

More from news
Approximately 20 fully matching, plus 582 partially matching documents found.

Latest Intelligence

Cancer immunotherapy: What's on the horizon?

targeting drugs from the likes of Crescendo Biologics and Pfizer, and Celldex’CD27-targeting antibody varlilumab which is in phase II testing for various solid tumour types. ... Meanwhile, AbbVie and Johnson &Johnson have both struck deals this year
Immuno-oncology is fundamentally changing what value means, but how quickly can the pharma marketing, educational and service model change to reflect that?

In recent years, biosimilars (highly similar copies of biologic medicines) have taken large shares of many markets.
Mylan sees the UK paving the way for an insulin game changer

4th generation of biologics.
‘How is your day?’

Plasma protein therapies are biologic medicines – derived from human plasma or recombinant analogues (that treat bleeding disorders) – that treat a range of life-threatening, chronic and genetic diseases.
Leo has its eyes on the prize

Advancing biologics and adding biomarkers for precision medicine is one of the steps we are going to see in the coming years. ... We have multiple approaches such as combining biologics where we may be able to address the inflamation and itch while

More from intelligence
Approximately 2 fully matching, plus 67 partially matching documents found.

Latest appointments

BMS appoints CCO, Stephen Davies joins Eisai and more

Commenting on her appointment, Schuermans said: “Sobi has unique capabilities, a heritage in biologics manufacturing, development and supply, and a very exciting future within the rare disease space.
Industry appointments

Most recently, Hassan built the oncology-focused biology, preclinical and biomarker units for Immunocore, overseeing early development and the first-in-human trial of a TCR based biologic targeting a melanoma
Nabriva Therapeutics appoints chief medical officer

medical affairs for small molecules and biologics.
Ipsen appoints Aidan Murphy as EVP, technical operations

Ipsen appoints Aidan Murphy as EVP, technical operations. He is promoted from senior VP biologics development and manufacturing. ... being senior vice president biologics development and manufacturing.
Andy Busch joins Shire as its CSO and head of research and development

both biologics and small molecules.”.

More from appointments
Approximately 7 fully matching, plus 45 partially matching documents found.

Latest from PMHub

It’s all about patient outcomes… right?

a novel biologic agent. ... Consequently, the roll-out of the novel biologic agent was conducted in a manner that was sensitive to the PCP/specialist interaction observed, ensured smooth communications and optimised patient outcomes.
Biotech: it's a people business

Biologic therapies have become a central part of modern day medicine and a key part of biotech and pharma portfolios.
Webcast: Biosimilars: Friend or Foe to Healthcare?

Webcast: Biosimilars: Friend or Foe to Healthcare? Understanding the opportunities for biosimilars and the threats to innovator biologics. ... Gain greater insight into what companies entering the market need to do to effectively launch their follow-on
Infographic: RA Perceptions

Partnership. An infographic highlights the key findings from the study. Biologic agents with novel mechanisms of action (such as Roche’ s RoActemra) are expected to outperform the overall EU biologics market ... Biosimilars (the approved follow-on
Biosimilars: Getting the flock to market

originator biologic agent, offering comparable efficacy and safety but with a lower acquisition cost. ... So biosimilars not only increase patient access to tried and trusted biologics, they may accelerate adoption of new agents.

More from PMHub
Approximately 7 fully matching, plus 41 partially matching documents found.

Featured jobs

Healthcare PR Director: £100, 000 – £120, 000 benefits

Director Healthcare PR Communications: Salary TBC

Graduate Scientific Editor: DOE

Healthcare Advertising Account Manager / Senior AM / AD: Salary TBC

Account Manager, Healthcare Advertising: Salary TBC

Account Director - Digital: Great salary and benefits

Lead Medical Copywriter, Healthcare Brand Communications, London: Excellent package

Scientific Team Lead: Competitive Salary

Editorial Director – Medical Education: Neg

Scientific Director: Highly Competitive Salary &Benefits

Experienced Editor, London, Medical Communications: Competitive package

Senior Account Manager - Med Comms: Highly Competitive Salary &Benefits

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Project / Account Manager (Medical Education): Salary TBC

Medical Strategic Director, Healthcare Advertising Agency: Salary TBC

Senior Account Director development role to Business Director, H...: Excellent package

Account Manager, Healthcare Communications: £32, 000 - £40, 000 benefits

Chief Medical Writer, Medical Communications, London, up to £90K...: up to £90K

Associate Medical Director: Salary TBC

Account Director: Negotiable

Senior Medical Writer (Remote Working): Competitive Salary Offered

Senior Account Executive – Medical Communications: Salary TBC

Director – Head of Public Affairs: Neg

SENIOR MEDICAL WRITER IN ONCOLOGY: Up to £60, 000.00 pension bonus

Account Manager- Manchester, Macclesfield or Glasgow: Negotiable

Subscribe to our email news alerts

PMHub

Add my company

Pegasus

Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...

Latest intelligence

In conversation with Pfizer’s Erik Nordkamp: Pfizer’s UK general manager talks to PME about the NHS at 70, the potential of pharma partnerships and some lessons from Europe...
Pharma social media: Posting frequency is down as companies take a ‘less is more’ approach...
The case for a second Brexit referendum: “We need the informed consent of the people”: Dr Phillip Lee MP is fighting to keep the UK in the EMA network - and for a second referendum...